Study Summary
The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of lymphocyte derived malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD30-CAR-transduced T cellsBIOLOGICAL
The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Southwest Hospital of Third Millitary Medical University | Chongqing | Chongqing Municipality | China |